Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 10/20 | 0.52 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | TAF1 | P21675 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 2/20 | 0.39 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559674 | 0.87 | PLK1 (0.68) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL4551405 | 0.87 | PLK1 (0.56) | PLK1MAPK7LRRK2BRD4BRDT | |
| SCHEMBL4552291 | 0.78 | PLK1 (0.65) | PLK1MAPK7LRRK2BRD4BRDT | |
| SCHEMBL4551690 | 0.76 | LRRK2 (0.59) | PLK1LRRK2BRD4BRDT | |
| SCHEMBL1560594 | 0.75 | PLK1 (0.71) | PLK1MAPK7LRRK2BRD4BRDT | |
| SCHEMBL1559127 | 0.74 | PLK1 (0.73) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL1559675 | 0.73 | PLK1 (0.53) | PLK1MAPK7DYRK1ALRRK2BRD4 | |
| SCHEMBL1559047 | 0.73 | PLK1 (0.74) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL1559727 | 0.72 | PLK1 (0.77) | PLK1MAPK7DYRK1ABRD4BRDT | |
| SCHEMBL1560408 | 0.72 | PLK1 (0.74) | PLK1MAPK7DYRK1ABRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | PLK1 1/4885MAPK7 1592/4885DYRK1A 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.